SGRY241220P15000
- 0.49
- 0.000.00%
Surgery Partners Newsroom
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
Surgery Partners, Inc. (NASDAQ:SGRY) Is Expected To Breakeven In The Near Future
Key Takeaways From Surgery Partners Analyst Ratings
Surgery Partners Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $35
Express News | Surgery Partners Inc : RBC Cuts Target Price to $35 From $49
Surgery Partners Is Maintained at Outperform by Macquarie
Surgery Partners Price Target Maintained With a $34.00/Share by Macquarie
Macquarie Maintains Surgery Partners(SGRY.US) With Buy Rating
Overreaction to Selloff: Surgery Partners' Undervalued Opportunity Amidst Strong Fundamentals
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $32
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $40
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $31 to $50
Surgery Partners Third Quarter 2024 Earnings: EPS Misses Expectations
Surgery Partners Analyst Ratings
Surgery Partners Down Over 11%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Surgery Partners Price Target Lowered to $34 From $35 at Macquarie
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating
Strong Q3 Performance and Strategic Growth Bolster 'Buy' Rating for Surgery Partners
Surgery Partners | 10-Q: Q3 2024 Earnings Report